Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain
1. INMB's stock is down 59%, trading at $2.14. 2. Volume spiked to 23.2 million, significantly above average. 3. Phase 2 trial results showed cognitive benefits for XPro in OBAD patients. 4. INMB plans to file for Breakthrough Therapy Designation with the FDA. 5. Company aims to define pivotal trial path in Q4 2025.